No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Astellas Pharma Inc., a venerable Japanese pharmaceutical enterprise established in 1923 and headquartered in Tokyo, operates globally in the research, development, manufacturing, and commercialization of a diverse range of medications. Its extensive product lineup addresses critical health needs, including various oncology treatments such as XTANDI for prostate cancer, XOSPATA, an FLT3 inhibitor for specific relapsed or refractory acute myeloid leukemia, and PADCEV for advanced urothelial cancer. For urological conditions, Astellas offers Betanis/Myrbetriq/BETMIGA to manage symptoms of overactive bladder, mirabegron for neurogenic detrusor overactivity in children, and Vesicare for OAB. Other notable pharmaceuticals include Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, Evrenzo for anemia associated with chronic kidney disease, and the immunosuppressants Prograf/Advagraf/Graceptor/ASTAGRAF, vital for preventing organ transplant rejection. The company also markets Funguard/MYCAMINE, an antifungal agent. Astellas actively fosters innovation through numerous strategic collaborations and partnerships. These include clinical trial agreements with pharmaceutical giants like Merck & Co., Inc. and CytomX Therapeutics, Inc. Demonstrating a broader approach to health, they collaborate with BANDAI NAMCO Entertainment Inc. on developing a smartphone exercise support application. In the realm of scientific discovery, Astellas maintains a research alliance with Harvard University for joint therapeutic and technological advancements. Further research initiatives involve Actinium Pharmaceuticals, Inc. to advance targeted radiotherapies leveraging their Antibody Warhead Enabling platform, an agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694, and a collaboration with Cytokinetics, Incorporated. A significant strategic alliance and license agreement exist with Minovia Therapeutics Ltd. to research, develop, and commercialize cell therapies for mitochondrial dysfunction.
www.astellas.comNo one on the platform currently holds 4503.T.
No tracked institution reports a position in 4503.T as of their last filing.
No one on the platform has traded 4503.T yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 15.4% | 13.6% | 17.1% | — | — | — |
| Rev. Growth % | 11.9% | 11.4% | ||||
| Profit Margin % | 13.6% | 6.7% | 10.4% | |||
| Free Cash Flow Margin % | 23.8% | 15.7% | 17.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $2.33T | +9.7% | $199.42 | $164.14–$278.79 | — | 12 |
| 2028 | $2.17T | -6.8% | $201.35 | $142.18–$295.22 | — | 12 |
| 2029 | $1.94T | -10.9% | $157.52 | $82.23–$265.82 | — | 12 |
| 2030 | $1.85T | -4.5% | $143.73 | $128.52–$156.39 | — | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $52.62 | $79.15 | +50.4% |
| 2026-04-27 | $30.58 | $24.29 | -20.6% |
| 2026-02-04 | $45.93 | $56.04 | +22.0% |
| 2025-10-30 | $29.81 | $44.22 | +48.3% |
| 2025-07-30 | $19.87 | $38.22 | +92.4% |
| 2025-04-25 | $21.32 | $41.84 | +96.2% |
| 2025-02-04 | $18.94 | $-54.55 | -388.0% |
| 2024-10-30 | $15.97 |
| $20.06 |
| +25.6% |
| +1.75% |
| $2.47T |
| — |
| 4523.TEisai Co., Ltd. | $4767.00 | +0.51% | $1.35T | — |
| 4528.TOno Pharmaceutical Co., Ltd. | $2353.50 | +0.68% | $1.11T | — |
Source: Financial Modeling Prep · peers by sector/industry